RU2015138544A - Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран - Google Patents
Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран Download PDFInfo
- Publication number
- RU2015138544A RU2015138544A RU2015138544A RU2015138544A RU2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- polynucleotide
- composition
- seq
- ogt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 56
- 238000000034 method Methods 0.000 title claims 47
- 108010090473 UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000029663 wound healing Effects 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 claims 50
- 239000002157 polynucleotide Substances 0.000 claims 50
- 102000040430 polynucleotide Human genes 0.000 claims 50
- 125000003729 nucleotide group Chemical group 0.000 claims 29
- 239000002773 nucleotide Substances 0.000 claims 27
- 239000003937 drug carrier Substances 0.000 claims 14
- 230000000295 complement effect Effects 0.000 claims 13
- 206010052428 Wound Diseases 0.000 claims 11
- 208000027418 Wounds and injury Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- -1 polyoxyethylene Polymers 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004055 small Interfering RNA Substances 0.000 claims 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 241000021559 Dicerandra Species 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 235000010654 Melissa officinalis Nutrition 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 229940072056 alginate Drugs 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000000865 liniment Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 2
- 229920001992 poloxamer 407 Polymers 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 239000003357 wound healing promoting agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01186—Glycogenin glucosyltransferase (2.4.1.186)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01255—Protein O-GlcNAc transferase (2.4.1.255)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Power Engineering (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775937P | 2013-03-11 | 2013-03-11 | |
| US61/775,937 | 2013-03-11 | ||
| PCT/US2014/023525 WO2014164805A1 (en) | 2013-03-11 | 2014-03-11 | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015138544A true RU2015138544A (ru) | 2017-04-18 |
Family
ID=51658978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015138544A RU2015138544A (ru) | 2013-03-11 | 2014-03-11 | Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170166897A1 (https=) |
| EP (1) | EP2970978A4 (https=) |
| JP (1) | JP2016513968A (https=) |
| KR (1) | KR20150126048A (https=) |
| CN (1) | CN105408480A (https=) |
| AU (1) | AU2014248966A1 (https=) |
| BR (1) | BR112015022701A2 (https=) |
| CA (1) | CA2905337A1 (https=) |
| CL (1) | CL2015002599A1 (https=) |
| MX (1) | MX2015012124A (https=) |
| RU (1) | RU2015138544A (https=) |
| SG (1) | SG11201507211YA (https=) |
| WO (1) | WO2014164805A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12146883B2 (en) * | 2018-12-06 | 2024-11-19 | Biocapital Holdings, Llc | Glucose sensors and methods of use thereof |
| CN111234022B (zh) * | 2019-12-16 | 2024-03-22 | 江苏省药物研究所有限公司 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
| CN112707955B (zh) * | 2020-12-21 | 2022-01-18 | 山东润德生物科技有限公司 | 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| AU6942598A (en) * | 1997-03-31 | 1998-10-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | O-linked glcnac transferase (ogt): cloning, molecular expression, and methods ofuse |
| EP1102786A4 (en) * | 1998-08-03 | 2002-03-06 | Univ East Carolina | AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS |
| EP2314321B1 (en) * | 1999-01-27 | 2014-06-04 | Coda Therapeutics, Inc. | Formulations comprising antisense nucleotides to connexins |
| RU2442989C2 (ru) * | 2005-12-22 | 2012-02-20 | Й-Оил Миллс, Инц. | СПОСОБ ОБНАРУЖЕНИЯ САХАРНЫХ ЦЕПЕЙ С GlcNAc, СИНТЕЗИРОВАННЫХ GnT-V |
| WO2010042228A2 (en) * | 2008-10-10 | 2010-04-15 | Cornell University | Methods for predicting disease outcome in patients with colon cancer |
| US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| JP2012083193A (ja) * | 2010-10-12 | 2012-04-26 | Univ Of Tokyo | ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体 |
-
2014
- 2014-03-11 WO PCT/US2014/023525 patent/WO2014164805A1/en not_active Ceased
- 2014-03-11 US US14/774,800 patent/US20170166897A1/en not_active Abandoned
- 2014-03-11 EP EP14779180.0A patent/EP2970978A4/en not_active Withdrawn
- 2014-03-11 JP JP2016501273A patent/JP2016513968A/ja not_active Withdrawn
- 2014-03-11 BR BR112015022701A patent/BR112015022701A2/pt not_active IP Right Cessation
- 2014-03-11 CN CN201480026966.0A patent/CN105408480A/zh active Pending
- 2014-03-11 SG SG11201507211YA patent/SG11201507211YA/en unknown
- 2014-03-11 MX MX2015012124A patent/MX2015012124A/es unknown
- 2014-03-11 KR KR1020157028279A patent/KR20150126048A/ko not_active Withdrawn
- 2014-03-11 RU RU2015138544A patent/RU2015138544A/ru not_active Application Discontinuation
- 2014-03-11 AU AU2014248966A patent/AU2014248966A1/en not_active Abandoned
- 2014-03-11 CA CA2905337A patent/CA2905337A1/en not_active Abandoned
-
2015
- 2015-09-11 CL CL2015002599A patent/CL2015002599A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015002599A1 (es) | 2016-08-26 |
| KR20150126048A (ko) | 2015-11-10 |
| CN105408480A (zh) | 2016-03-16 |
| JP2016513968A (ja) | 2016-05-19 |
| SG11201507211YA (en) | 2015-10-29 |
| AU2014248966A1 (en) | 2015-10-29 |
| BR112015022701A2 (pt) | 2018-09-25 |
| US20170166897A1 (en) | 2017-06-15 |
| EP2970978A4 (en) | 2016-11-02 |
| CA2905337A1 (en) | 2014-10-09 |
| MX2015012124A (es) | 2016-04-28 |
| EP2970978A1 (en) | 2016-01-20 |
| WO2014164805A1 (en) | 2014-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506240A5 (https=) | ||
| JP2010532163A5 (https=) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2011508605A5 (https=) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2011506447A5 (https=) | ||
| JP2010512404A5 (https=) | ||
| BR112015024764B1 (pt) | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem | |
| NO333254B1 (no) | Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. | |
| JP2018533956A5 (https=) | ||
| RU2015138544A (ru) | Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран | |
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| Mansour et al. | miRNAs and their multifaceted role in cutaneous wound healing | |
| EP3491129A1 (en) | Methods of treating osmidrosis | |
| JP2016513968A5 (https=) | ||
| JP2025511854A (ja) | 非アルコール性脂肪肝疾患の治療 | |
| CN102533755A (zh) | 人miR-328反义核酸及其应用 | |
| RU2015112131A (ru) | КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| CN116173218B (zh) | 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途 | |
| WO2016069717A1 (en) | Inhibitors of mirnas in regulation of arterial stiffness and uses thereof | |
| CN102140469B (zh) | 人miR-1233反义核酸及其应用 | |
| CN102643811B (zh) | 人miR-1229的反义寡聚核苷酸及其应用 | |
| JP7847874B2 (ja) | ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物 | |
| EP4162046B1 (en) | Treatment method of left ventricular dysfunction following an acute myocardial infarction | |
| CN102643813B (zh) | 人miR-504的反义寡聚核苷酸及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180504 |